Brokerages Set Aquestive Therapeutics Inc (AQST) PT at $20.29

Aquestive Therapeutics Inc (NASDAQ:AQST) has earned an average recommendation of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $20.46.

AQST has been the subject of a number of analyst reports. Zacks Investment Research lowered Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 16th. Lake Street Capital restated a “buy” rating on shares of Aquestive Therapeutics in a research report on Wednesday, February 20th. BMO Capital Markets dropped their price target on Aquestive Therapeutics from $24.00 to $21.00 and set an “outperform” rating for the company in a research report on Friday, March 15th. Wedbush set a $30.00 price target on Aquestive Therapeutics and gave the company a “buy” rating in a research report on Friday, March 22nd. Finally, HC Wainwright initiated coverage on Aquestive Therapeutics in a research report on Monday, April 22nd. They issued a “buy” rating and a $10.00 price target for the company.

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. bought a new position in Aquestive Therapeutics in the third quarter valued at about $8,254,000. Vanguard Group Inc. bought a new position in Aquestive Therapeutics in the third quarter valued at about $8,055,000. Vanguard Group Inc bought a new position in Aquestive Therapeutics in the third quarter valued at about $8,055,000. Bank of Montreal Can lifted its holdings in Aquestive Therapeutics by 245,514.3% in the fourth quarter. Bank of Montreal Can now owns 120,351 shares of the company’s stock valued at $758,000 after acquiring an additional 120,302 shares during the period. Finally, New York State Common Retirement Fund bought a new position in Aquestive Therapeutics in the fourth quarter valued at about $28,000. Institutional investors and hedge funds own 66.12% of the company’s stock.

NASDAQ:AQST traded up $0.43 during trading hours on Wednesday, hitting $5.35. 150,476 shares of the stock were exchanged, compared to its average volume of 110,590. The company has a current ratio of 1.89, a quick ratio of 1.71 and a debt-to-equity ratio of 4.23. The firm has a market cap of $133.62 million and a P/E ratio of -1.91. Aquestive Therapeutics has a 52-week low of $4.50 and a 52-week high of $20.70.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.10). The firm had revenue of $12.64 million during the quarter, compared to analyst estimates of $10.66 million. On average, research analysts forecast that Aquestive Therapeutics will post -2.31 earnings per share for the current year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.

Recommended Story: Marijuana Stocks

Analyst Recommendations for Aquestive Therapeutics (NASDAQ:AQST)

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.